- Home
- USEA vs PULM Comparison
USEA vs PULM Comparison
Compare USEA & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- PULM
- Stock Information
- Founded
- USEA 2004
- PULM 2003
- Country
- USEA Greece
- PULM United States
- Employees
- USEA N/A
- PULM N/A
- Industry
- USEA Marine Transportation
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- PULM Health Care
- Exchange
- USEA Nasdaq
- PULM Nasdaq
- Market Cap
- USEA 15.6M
- PULM 18.3M
- IPO Year
- USEA N/A
- PULM N/A
- Fundamental
- Price
- USEA $1.63
- PULM $4.32
- Analyst Decision
- USEA
- PULM
- Analyst Count
- USEA 0
- PULM 0
- Target Price
- USEA N/A
- PULM N/A
- AVG Volume (30 Days)
- USEA 56.0K
- PULM 5.3K
- Earning Date
- USEA 11-11-2025
- PULM 10-16-2025
- Dividend Yield
- USEA 7.74%
- PULM N/A
- EPS Growth
- USEA N/A
- PULM N/A
- EPS
- USEA N/A
- PULM N/A
- Revenue
- USEA $42,025,000.00
- PULM $3,000.00
- Revenue This Year
- USEA N/A
- PULM N/A
- Revenue Next Year
- USEA N/A
- PULM $134.88
- P/E Ratio
- USEA N/A
- PULM N/A
- Revenue Growth
- USEA N/A
- PULM N/A
- 52 Week Low
- USEA $1.00
- PULM $4.26
- 52 Week High
- USEA $2.10
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- USEA 61.90
- PULM 47.71
- Support Level
- USEA $1.55
- PULM $4.32
- Resistance Level
- USEA $1.74
- PULM $4.85
- Average True Range (ATR)
- USEA 0.10
- PULM 0.24
- MACD
- USEA 0.01
- PULM -0.03
- Stochastic Oscillator
- USEA 90.74
- PULM 51.39
About USEA United Maritime Corporation
United Maritime Corp is an international shipping company. It is engaged in seaborne transportation services. The group currently operates a fleet of seven dry bulk vessels, comprising three Panamax, two Capesize and two Kamsarmax vessels with an aggregate cargo-carrying capacity of approximately 750,758 dwt.
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).